Warner Bros Shareholders Approve Paramount Merger, Vote Against Zaslav Pay Package

Warner Bros. Discovery shareholders approved Paramount Skydance’s $111 billion acquisition, a $31-per-share cash deal, but voted against executive compensation packages tied to the merger. CEO David Zaslav’s exit package is valued at at least $550 million, including $34.2 million in cash severance, $517.2 million in equity, and up to $335 million in tax reimbursements. The transaction still requires regulatory approval in the U.S. and Europe and faces opposition from state attorneys general and Hollywood unions.

Analysis

The shareholder vote removes a governance overhang, but it does not remove deal-risk beta. The market is likely to treat WBD less like a standalone equity and more like a contingent claim on closing probability; that shifts the relevant catalyst window from the next few weeks to the regulatory calendar over the next 3-9 months. In that setup, upside is increasingly capped while downside remains binary if antitrust scrutiny intensifies or conditions become too punitive.

The more interesting second-order effect is on competitors, especially NFLX. A combined Paramount/WBD would create a more rationalized library-and-franchise owner with a stronger hand in bundling and sports/news positioning, but also a faster path to cost cuts that can temporarily widen pricing pressure across streaming. That can force Netflix to defend share with higher content spend or more aggressive packaging, which is why NFLX may see subtle multiple compression even without direct transaction exposure.

The compensation backlash matters less as a headline and more as a sign that shareholders are unlikely to support any protracted value leakage if the deal stalls. If regulators delay or reshape the merger, management credibility and employee retention become a real risk: the two-year non-compete / non-solicit structure suggests the real asset being protected is talent, and that can weaken execution if closing slips into 2026. The most asymmetrical risk is not closing failure alone, but a long limbo that freezes capital allocation and keeps both companies strategically distracted while competitors keep shipping product.

Consensus appears too focused on the transaction as inevitable. The better read is that the market is underpricing process risk: state AG action and European review can convert a clean shareholder approval into a drawn-out remedies negotiation, and any requirement to divest assets would compress the economics that justified the bid. That makes the current setup more suitable for trading optionality than for outright directional conviction.

Key Decisions for Investors

• WBD: reduce or hedge long exposure into regulatory headlines; treat the stock as event-driven optionality with a 3-9 month outcome window, not a core holding.
• Pair trade: long NFLX / short WBD on any merger-related rally; if the deal closes, WBD becomes a fixed-value outcome while NFLX retains standalone compounding and less regulatory overhang.
• Buy WBD downside protection for the next 4-6 months (put spread rather than outright puts) to express antitrust/remedy risk while limiting theta burn if approvals drift rather than fail.
• If WBD gap-ups on no-news, fade the move with a tight stop: asymmetric downside remains if DOJ/Europe widen conditions, while upside is largely capped near deal value.
• Monitor state AG and EU milestones closely; if formal remedies appear likely, rotate from WBD optionality into NFLX relative strength, since the market will likely de-rate M&A certainty faster than it re-rates standalone media assets.